Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADALAT vs ADVIL COLD AND SINUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to analgesic, anti-inflammatory, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Temporary relief of sinus congestion and pressure,Temporary relief of nasal congestion,Temporary reduction of fever,Relief of minor aches and pains associated with the common cold or flu
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours. Do not exceed 1200 mg ibuprofen and 180 mg pseudoephedrine per day.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Ibuprofen: 2-4 hours (terminal; rapid elimination, no accumulation with intermittent use). Pseudoephedrine: 4-8 hours (terminal; prolonged in alkaline urine, up to 16 hours at p H 8).
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Ibuprofen is primarily metabolized by CYP2C9 and CYP2C8. Pseudoephedrine is partially metabolized in the liver by N-demethylation.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Renal excretion of unchanged drug and metabolites: ibuprofen ~45-60% (primarily as conjugated metabolites, <10% unchanged), pseudoephedrine ~70-90% unchanged. Biliary/fecal elimination accounts for <10% for both components.
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
Ibuprofen: ~99% primarily to albumin. Pseudoephedrine: negligible (<10% bound to plasma proteins).
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Ibuprofen: 0.1-0.2 L/kg (low Vd, indicating limited tissue distribution). Pseudoephedrine: 2.5-3.5 L/kg (high Vd, extensive tissue distribution including CNS).
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
Oral: ibuprofen ~80-100% (rapidly absorbed, no significant first-pass). Pseudoephedrine ~100% (well absorbed, minimal first-pass metabolism).
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
GFR 30-89 m L/min: Use lowest effective dose for shortest duration; monitor renal function. GFR <30 m L/min or dialysis: Contraindicated.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Child-Pugh Class A: No adjustment; use with caution. Child-Pugh Class B or C: Avoid use.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Children <12 years: Do not use. Children ≥12 years: Same as adult dosing; 1-2 tablets every 4-6 hours as needed; maximum 6 tablets in 24 hours.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
Use lowest effective dose for shortest duration; avoid chronic use. Reduce initial dose to 1 tablet every 6-8 hours due to increased risk of renal impairment, GI bleeding, and cardiovascular events.
None
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Cardiovascular thrombotic events, gastrointestinal bleeding/ulceration/perforation, hypertension, renal toxicity, serious skin reactions, anaphylactoid reactions, exacerbation of asthma, and drug interactions including with ACE inhibitors, diuretics, and lithium.
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
Hypersensitivity to ibuprofen, aspirin, or other NSAIDs; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; patients with severe hypertension or coronary artery disease; patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs; concurrent use of other sympathomimetics; in the setting of CABG surgery.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
Take with food or milk to reduce gastrointestinal irritation. Avoid alcohol consumption as it increases the risk of NSAID-related gastric ulcers and bleeding. High-sodium foods may exacerbate hypertension in patients sensitive to the pressor effects of pseudoephedrine.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
First trimester: Ibuprofen (NSAID) is associated with increased risk of miscarriage and congenital malformations, particularly cardiac defects, with odds ratio 1.86 (95% CI 1.32-2.62) for any malformation and 1.86 (95% CI 1.32-2.62) for cardiac malformations. Second trimester: Risk of oligohydramnios and premature closure of ductus arteriosus after 20 weeks. Third trimester: Avoid after 30 weeks due to risk of premature ductus arteriosus closure and oligohydramnios; after 32 weeks, increased risk of necrotizing enterocolitis, intracranial hemorrhage, and renal impairment in neonate (renal agenesis/dysgenesis). Pseudoephedrine: First trimester – possible increased risk of gastroschisis (odds ratio 1.8, 95% CI 1.0-3.2) and small intestinal atresia. Second and third trimesters: potential uteroplacental vasoconstriction leading to fetal hypoxia; risk of prematurity and low birth weight.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
Ibuprofen: M/P ratio 0.005–0.006; low transfer into breast milk; AAP compatible; theoretical risk of platelet dysfunction in neonate. Pseudoephedrine: M/P ratio 2.6–3.5 (concentrated in milk); estimated infant dose 4.3% of maternal weight-adjusted dose; may cause irritability and sleep disturbances in infant; may reduce milk production by up to 24%. Caution advised; avoid in lactation if possible.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
Ibuprofen: No dose adjustment required; however, use lowest effective dose and shortest duration; avoid after 30 weeks gestation. Pseudoephedrine: No specific dose adjustment recommended based on pharmacokinetic changes, but use with caution due to vasoconstrictive effects; reduced efficacy may be observed due to increased plasma volume and renal clearance.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Advil Cold and Sinus is a fixed-dose combination of ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen inhibits COX-1/2, reducing prostaglandin synthesis, while pseudoephedrine is an α-adrenergic agonist causing vasoconstriction in nasal mucosa. Use cautiously in patients with hypertension, cardiovascular disease, or renal impairment due to pseudoephedrine's pressor effects and ibuprofen's potential to reduce renal blood flow and antagonize antihypertensives. Avoid in patients with severe coronary artery disease, uncontrolled hypertension, or concurrent MAOI use. Max duration: 3 days for sinus symptoms, 5 days for pain. Monitor for NSAID-induced GI bleeding, especially in elderly or those on anticoagulants/aspirin.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
Do not take more than directed; do not exceed 6 caplets in 24 hours.,Avoid use with other products containing ibuprofen or other NSAIDs, including aspirin, to prevent overdose and serious side effects.,Discontinue use and seek medical attention if symptoms worsen, persist >3 days for sinus or >5 days for pain, or if new symptoms occur.,Take with food or milk to reduce stomach upset; avoid alcohol to lower risk of GI bleeding.,If you have high blood pressure, heart disease, thyroid disease, diabetes, or difficulty urinating due to prostate enlargement, consult a doctor before use.,Do not use if you are taking a prescription monoamine oxidase inhibitor (MAOI) or for 2 weeks after stopping an MAOI drug.,Pregnant or breastfeeding women should not use this product; ibuprofen is contraindicated in third trimester due to risk of premature closure of ductus arteriosus.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADALAT vs ADVIL COLD AND SINUS, answered by our medical review team.
ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. ADVIL COLD AND SINUS is a NSAID/Decongestant Combination that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to analgesic, anti-inflammatory, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADALAT and ADVIL COLD AND SINUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. The standard adult dose of ADVIL COLD AND SINUS is: 1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours. Do not exceed 1200 mg ibuprofen and 180 mg pseudoephedrine per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADALAT and ADVIL COLD AND SINUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. ADVIL COLD AND SINUS is classified as Category C. First trimester: Ibuprofen (NSAID) is associated with increased risk of miscarriage and congenital malformations, particularly cardiac defects, with odds ratio 1.86 (95% CI 1.32-2.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.